Application of acoustic droplet vaporization in ultrasound therapy by unknown
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Microbubbles have been used widely both in the ultrasonic diagnosis to enhance the contrast of vasculature and in
ultrasound therapy to increase the bioeffects induced by bubble cavitation. However, due to their large size, the
lifetime of microbubbles in the circulation system is on the order of minutes, and they cannot penetrate through the
endothelial gap to enter the tumor. In an acoustic field, liquefied gas nanoparticles may be able to change the state
and become the gas form in a few cycles of exposure without significant heating effects. Such a phenomenon is called
as acoustic droplet vaporization (ADV). This review is intended to introduce the emerging application of ADV. The
physics and the theoretical model behind it are introduced for further understanding of the mechanisms. Current
manufacturing approaches are provided, and their differences are compared. Based on the characteristic of phase shift,
a variety of therapeutic applications have been carried out both in vitro and in vivo. The latest progress and interesting
results of vessel occlusion, thermal ablation using high-intensity focused ultrasound (HIFU), localized drug delivery to
the tumor and cerebral tissue through the blood-brain barrier, localized tissue erosion by histotripsy are summarized.
ADV may be able to overcome some limitations of microbubble-mediated ultrasound therapy and provide a novel
drug and molecular targeting carrier. More investigation will help progress this technology forward for clinical
translation.
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Background
Ultrasound has been used in clinics since 1940s, mostly
for diagnostic and physiotherapy purposes at low intensity.
With the advance of electrics, computer technology, and
transducer design in the 1980s, moderate or high-
intensity ultrasound was applied in medicine with promis-
ing results. Since then, therapeutic ultrasound is emerging
as an interesting and important research topic not only
for physicists and engineers but also for medical practi-
tioners. Cavitation is one of the important mechanisms in
ultrasound therapy [1, 2]. However, the distribution of
bubble nuclei in the soft tissue and blood is quite sparse.
In order to induce the desired bioeffect in the acoustic
field using low energy in vivo, artificial bubble nuclei can
be introduced for cavitation. Ultrasound contrast agents
(UCAs), such as gaseous microbubbles, have been used in
sonographic diagnosis in cardiology clinics as cavitation
enhancers in some therapeutic applications, such as blood
clot fragmentation, tissue erosion, drug delivery, gene
transfection, and necrosis formation in the thermal abla-
tion [3–7]. However, UCAs have relatively large size (1–
10 μm) and short in vivo circulation lifetime (i.e. a few mi-
nutes). Thus, re-administration of UCAs requires repeated
sonication. Furthermore, these microbubbles cannot ex-
travasate into tumor tissue for efficient targeting of agents
to deep within the tumor.
The phenomenon of acoustic droplet vaporization
(ADV), in which the phase shift of the core from liquid
to gas triggered by an acoustic wave, was been described
in the 1990s and was used extensively in imaging for
preclinical trials [8–10]. The physics are based on the
vapor pressure of the liquid, which is a function of
temperature, and not necessarily based upon the liquid
chemistry. In theory, ADV could be employed with any
liquid that has a normal boiling point near or below the
body temperature. Fluorocarbons are good candidates,
particularly the perfluorocarbons (PFCs) because they
have low solubility in aqueous formulations and rela-
tively low toxicity. Perfluoropentane (PFC5) is perhaps
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the most commonly used in ADV because of its favor-
able transition temperature (~29 °C), its good combin-
ation of high vapor pressure, low solubility in blood,
price, and availability. Due to the low solubility and dif-
fusivity of PFC gases in water, bubbles can remain stable
in an aqueous solution much longer than air bubbles in
the same size [11]. Clearance of PFC nanoparticles oc-
curs not through metabolism but slow dissolution into
the surrounding medium. The resulting half-life in the
tissue is much longer than that of microbubble, ranging
from 4 days (i.e., perfluorooctylbromide) to 65 days (i.e.,
perfluorotripropylamine). Since these liquid droplets
were much smaller than gas bubbles, they could traverse
the lungs and provide contrast in the left heart by ADV
better than the Food and Drug Administration (FDA)-
approved contrast agent Albunex in the diagnosis of
ventricular opacification [12, 13]. Phase-change colloids
for ultrasonic imaging resulted in the advent of Echo-
Gen™ in 1996. It shows that PFC nanodroplets (~200 nm
in diameter) can be vaporized with short ultrasound
pulses emitted from clinical diagnostic machines. How-
ever, the diagnostic use declined rapidly with the advent
of other imaging agents. Some PFCs exhibit echogenicity
due to a lower acoustic impedance than water, but not
as significant as that of microbubbles. Sonography with
the aid of UCAs has been proved to be a sensitive and
inexpensive imaging technique in cardiovascular and
oncological diagnosis. Currently, this technology has
been approved by the FDA for the echocardiographic
examination of wall motion abnormalities and ventricu-
lar contraction. So, the use of ADV for standard clinical
imaging of cardiovascular organs and systems may not
experience much resurgence in the future.
Capillaries in the diameter between 5 and 10 μm have
only a single layer of endothelial cells. Although capillary
vasculature in normal tissues has tight inter-endothelial
junctions and therefore inhibits extravasation of nano-
particles, a variety of tumors have a porous and disorga-
nized defective microvasculature with pore cutoff size
ranging between 380 and 780 nm, which permits the so
called enhanced permeability and retention (EPR) effect
[14]. This characteristic allows submicron vesicles to
penetrate tumor’s capillaries in a passive way. In addition
to the EPR, tumors also have poor lymphatic drainage,
which further ensures prolonged circulation time of
nanoparticles. To avoid both extravasation to normal tis-
sues and recognition by cells of the reticulo-endothelial
system (RES), the nanoparticles are usually coated with
polyethylene glycol (PEG) chains to suppress blood pro-
tein adsorption.
Microdroplets encapsulated in albumin or lipid shells in
ADV are used to generate embolization and show promise
for spatially and temporally targeted and substantial tissue
occlusion. Both intracardiac and intravenous injections
repeatedly could produce ADV in chosen arteries (i.e.,
renal or segmental arteries) as seen by sonography. Local-
ized cortex occlusion was achieved with a maximum re-
gional flow reduction of >90 % and an average organ
perfusion reduction of >70 % using intracardiac injections,
and vaporization from intravenous injections resulted in a
substantial echogenicity increase with an average half-life
of 8 min per droplet dose, which could result in the onset
of cell death and possible tumor treatment via ischemic
necrosis [15, 16]. Ninety percent of the pefluoropentane
(PFP) concentration in the blood can be eliminated from
the body within 10 min after their administration, which
diminishes the risk of toxicity [17].
For nanosized droplets, surface tension effects domin-
ate the largest expansion. Therefore, a sharp decline in
the expansion factor is found in the lower nanometer
range of droplets. In order to utilize the EPR effect for
enhanced intratumoral diffusion, droplets of 100–
200 nm in size is preferred. However, these droplets have
the expansion factor of 2.5–3.5, resulting in bubbles on
the order of 250–700 nm. Although the vaporized bub-
bles still have cavitation effects for enhanced thermal
therapy or drug delivery, they are much smaller than
preferable for diagnostic imaging (on the order of 1–
5 μm). Post-extravasation droplet/bubble coalescence
may increase echogenicity, but no in vivo evidence has
confirmed such hypothesis. Therefore, there exists a de-
sign trade-off in echogenicity and droplet diffusivity [18].
In comparison, a transition occurs at the low microm-
eter range because of the dominant effect of the lowest
ambient pressure, approximately 25 times the original
diameter for frequencies between 1.5 and 8 MHz at the
threshold from 4.5 to 0.75 MPa peak rarefactional pres-
sure, respectively. This agent might be useful for tissue
occlusion in cancer treatment, as well as for phase aber-
ration corrections in acoustic imaging [8]. But, its pene-
tration to interstitial space is limited.
Temporally and spatially controlled therapy (i.e., drug
delivery) remains a holy grail in medicine. Great effort
has been devoted by generations of scientists and physi-
cians to design an approach or system that only delivers
therapy at a certain target site, leaving healthy tissue un-
harmed. Different internal stimuli (i.e., pH) or external
stimuli, such as electromagnetic waves or magnetic and
electrochemical forces, have been used to trigger such a
process. Among them, ultrasound has the advantages of
safety, accessibility, cost-effectiveness, and the capabil-
ities of combined imaging and therapy. Plenty of studies
are being carried out in the field of triggered drug re-
lease from microbubbles and agent uptake into cells
whose membranes become temporarily permeablized
due to localized acoustic bubble cavitation. So, it is rea-
sonable to expect that phase-shift contrast agents may
be a novel way of achieving ultrasound therapy with
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great control of spatial and temporal activation, such as
localized drug delivery by nanoemulsion as shown in
Fig. 1.
Acoustic activation with significant temporal and
spatial specificity has led to a diverse set of in vitro and
in vivo applications, not only strictly for intravascular
administration because liquid PFC emulsions have a
broad range of sizes. In the last decade, ADV was pro-
posed and explored for embolic occlusion therapy, mo-
lecular imaging, drug delivery, aberration correction,
high-intensity focused ultrasound (HIFU) sensitization,
and tissue erosion by histotripsy [8, 16, 19, 20]. In this
review paper, the physics of acoustic droplet
vaporization is first introduced to understand this
phenomenon. The manufacture processes are summa-
rized briefly. Then, several medical applications are
listed and followed by the discussion of the future
development.
Physics
Liquids possess a vapor pressure, which is defined as the
pressure of the specified gas in equilibrium with its own
liquid in a closed system at a specified temperature. The
vapor pressure increases as the temperature of the con-
densed phase increases. When the surrounding pressure
is greater than the vapor pressure, the condensed phase
remains in its condensed form (liquid) in spite of slow
dissolution and diffusion into the aqueous phase. In con-
trast, when the surrounding local pressure is below the
vapor pressure, the liquid molecules will quickly escape
to form a gas phase (boiling) without any necessary
changes in temperature. The acoustic aspect of ADV oc-
curs because the acoustic waves are used to manipulate
the local pressure of the liquid, thus controlling the drive
of phase transition, either from a liquid to gas or from
gas to liquid. However, such transformation may not
happen instantaneously because of the enthalpy required
for vaporization and the presence of nucleation event re-
quired to initiate the formation of the gas phase. A li-
quid above its boiling point is called “superheated”.
Impurities (i.e., particle nidus), foreign surfaces, and
physical stresses (i.e., shear or shock event) increase the
probability of nucleation within a superheated liquid.
Such probability is also a strong function of the amount
of superheating above the boiling point, in which super-
heating is often referred to as the “driving force” for nu-
cleation. Because some PFCs have boiling points near
physiological temperatures, droplets can be designed in
or near a superheated state. Laplace pressure is the add-
itional pressure imposed upon the interior fluid of a
droplet because of the surface tension (or interfacial en-
ergy) between the two immiscible phases that com-
presses the liquid or gas inside the droplet.
ΔP ¼ 2γ
r tð Þ ð1Þ
where γ is interfacial energy and r(t) is the bubble radius.
Therefore, expansion of nanodroplets is expected to be
less than that of microdroplets, and a superheated drop-
let can be vaporized by ultrasonic radiation into a large
and stable bubble that will not return to the liquid emul-
sion state because of the reduction of the Laplace pres-
sure. PFC droplets injected in vivo do not vaporize
spontaneously due to the presence of Laplace pressure,
and hence, their boiling point elevates [6]. The hydro-
phobicity of liquid PFCs leads to relatively high inter-
facial surface tension when dispersed in water. So, the
Laplace pressure of the liquid core is on the order of at-
mospheres. Low boiling point of PFCs, such as perfluoro-
pentane, enables the vaporization using lower acoustic
amplitude [7]. During the phase of rarefractional acoustic
Fig. 1 Schematic diagram of extravasation of nanoemulsion through endothelial cell gaps due to enhanced permeability and retention (EPR) and
expansion to microbubbles by in situ phase transition after ultrasound exposure and release of loaded drugs
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pressure, the internal pressure, if less than the vapor pres-
sure (called “subpressurization”), enables gas formation
(see Fig. 2). The probability of homogeneous nucleation of
a growing gas bubble is proportional to the time window
(at constant subpressurization) and increases exponen-
tially with the magnitude of subpressurization. However,
subpressurization of perfluorocarbon liquid droplets can
also lead to no gas formation [8, 21]. Apparent subpressur-
ization is analogous to the apparent superheating, in which
the vapor pressure at a temperature above the normal boil-
ing point is still not greater than the local pressure inside
the droplet even with sufficiently large Laplace pressure.
This may be due to the absence of a nucleation event.
The ambient pressure, P, and the temperature, T, re-
quired to induce phase shift to droplet are approximately
described by the Antoine vapor-pressure equation based




where A, B, and C are constants determined experimen-
tally at a particular temperature range and P is the ambi-
ent pressure. A modified ideal gas law equation with
consideration of the Laplace pressure is used to predict
the size of the expanded bubble, rg,
ρlRTr
3





where rl is the radius of the liquid droplet, m is the
molar mass, R is the ideal gas constant.
ADV bubble dynamics can be described by multiple
stages following empirical laws (see Fig. 3) [22]: (1) a
microsecond-long nucleation stage with a linear growth
rate; (2) a stage lasting several microseconds, where a linear
growth rate is observed, but smaller than the previous
stage; and (3) a stage up to 200 μs in duration with a non-
linear growth rate where the vapor bubble reaches 90–95 %
of its final size, before asymptotically reaching its final size.
PFC mass evaporation rate may be predicted by the kinetic
theory limits to the mass flux that can be attained in the
phase change process [23] and validated in experiment on a
time scale up to 600 μs [22].
The droplet vaporization dynamics have three distinct
regimes (see Fig. 4). Regime I begins with the start of
ultrasound and is prior to nucleation. It is characterized
by shape deformations and oscillatory translations of the
droplet within the surrounding fluid on the order of
100 nm along the propagation direction of the applied
ultrasound. During the oscillatory translations, the drop-
lets experience a random walk component. Regime II is
characterized by the growth of a vapor bubble during
the ultrasonic exposure enhanced by ultrasound-driven
rectified heat transfer. The growth of the vapor bubble
in this regime is composed of two components at differ-
ent time scales. The first component is a monotonic ex-
pansion with a typical velocity around 5–10 m/s at a
typical size near 10 μm. The second component is a si-
nusoidal perturbation due to successive vaporization and
condensation cycles driven by the applied ultrasound.
Nucleation is a highly stochastic process and could
occur as early as in the second pressure cycle. The high
Fig. 2 Schematic diagram of a gas phase forms around the emulsion droplet when the local wave pressure drops below the vapor pressure of
the perfluorocarbon minus the Laplace pressure
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phase conversion rate and the rapid bubble growth in
this regime suggest the dominant role of rectified heat
transfer. Rectified heat transfer is the net effect of the
decreased heat transfer during the contraction of the
vapor bubble surface, which is lower than the increase of
heat transfer during the surface expansion. Regime III is
a continued growth of the vapor bubble fully dominated
by heat transfer after the termination of ultrasound ex-
posure and is characterized by a monotonic and rela-
tively slow expansion. The overpressure between the
inside and outside of the vapor bubble in regime III is
small (of order 5 kPa). It suggests that the inertial pro-
cesses occur fast enough to allow the vapor bubble
growth and are not limiting this process [24].
Fig. 3 High-speed photography and size of ADV process with initial droplet diameter of 17 μm produced by a single 17-cycle ultrasonic pulse at
a frequency of 3.5 MHz and peak negative pressure of 10.8 MPa, with courtesy of [22]
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Acoustic cavitation is one possible mechanism of
vaporization. However, the ADV threshold is found less
than the inertial cavitation (IC) threshold. Thus, an IC
event is not necessary to cause vaporization, though IC
nuclei, such as ultrasound contrast agent and polystyr-
ene microspheres, external to the droplet can lower the
ADV threshold. ADV occurs first and may provide a
bubble then going through IC. Because the IC threshold
remained constant with different gas saturation of the
bulk fluid and the droplet diameter, it is likely that the
nucleus for IC is not external to the droplet and may be
the ADV bubble itself. In addition, it is possible to
achieve ADV with or without IC [25]. Meanwhile, the
intensity required to produce higher harmonics (the on-
set of stable cavitation) using the Fourier transform to
the acoustic emission signals measured by passive cavita-
tion detection (PCD) was about 10-fold greater than the
occurrence of the fundamental frequency (phase shift).
The acoustic intensity required for the baseline shift (the
onset of IC) was about sixfold higher than that required
for the higher harmonic frequencies [26]. Larger droplet
requires less acoustic intensity to produce IC. PFC6
nanoemulsions at 476 kHz required higher intensity for
phase shift compared to PFC5 while opposite conclu-
sions were found at 20 kHz [26].
High-speed photography of the nucleation of the gas
phase shows that the bubble forms within the liquid
PFC and not at the liquid PFC/water interface [27–29].
The ADV threshold has been found to decrease with in-
creasing frequency, whereas the cavitation threshold in
liquids is expected to increase with increasing frequency.
The threshold pressure decreases with increasing size of
the droplet. Acoustic droplet vaporization is initiated by
a combination of two phenomena: highly nonlinear dis-
tortion of the acoustic wave before it hits the droplet
and focusing of the distorted wave by the droplet itself.
At high excitation pressures, nonlinear distortion causes
significant superharmonics with wavelengths on the order
of the droplet size (see Fig. 5). These superharmonics
strongly contribute to the focusing effect. The focused
pressure increases the chance of nucleation. The larger
the droplet size, the stronger the focusing. The smaller
nanodroplets will require a higher frequency for activation
[30]. Smaller droplets (<20 μm) had the initial nucleation
site in the hemisphere closer to the ultrasound source ver-
sus initial nucleation in larger droplets (>20 μm) formed
Fig. 4 a–c A set of consecutive images showing acoustic droplet vaporization taken at 18.5 Mfps at an ambient temperature of 41 °C in three
distinct regimes by 10-cycle ultrasonic pulse at a frequency of 3.5 MHz and peak negative pressure of 4.5 MPa and d, e two typical examples of
the time dependent curves of the outer radius of the droplet/bubble complex obtained from the vaporization at ambient temperature of 41 and
50 °C, respectively, with courtesy of [24]
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further from the ultrasound transducer. As droplet size
decreased, the wavelength begins to be of similar or longer
than the droplet diameter, and the initial nucleus traverses
across the axis of acoustic propagation and forms prox-
imal to the acoustic source. For droplets smaller than the
half wavelength, the carrier frequency is unable to refocus
in the droplet; thus, inclusion of harmonics better de-
scribes the location of the initial nucleation for small
droplets. This may suggest an increased reliance on higher
pressures from higher harmonics for ADV of smaller drop-
lets. Mechanistically, acoustic lensing within the droplet
may enhance the development of large local negative pres-
sure resulting in a cavitation-like event (i.e., nucleation site
formation and onset of the ADV process). Once formed,
the nucleation site appears stable and serves as a source for
conversion from liquid to gaseous PFC, generating a high-
pressure bubble quickly undergoing rapid expansion to its
equilibrium diameter [31]. The extent of superharmonic fo-
cusing is negligible for the droplet size (<400 nm) and fre-
quencies (≤3 MHz).
The behavior of vaporized submicron droplets immedi-
ately following vaporization is different to their micronsized
counterparts. The efficiency of droplet vaporization is
dependent on the initial droplet nucleation rate, and the
stability of the newly created bubbles following vaporization
is determined by recondensation into the liquid form due
to an increase in Laplace pressure. There is a threshold
bubble radius of approximately 800 nm (in concordance
with the theoretical prediction using the Homogeneous
Nucleation Theory) above which the bubbles are stable
against recondensation and below which uncoated bubbles
are prone to recondensation. Long interval time does not
significantly affect the threshold pressure for recondensa-
tion. The efficiency of initial droplet nucleation is quite high
(on the order of at least 10 %), as approximately ten drop-
lets may be sufficient for the production of a detectable
amount of bubbles with comparable echogenicity as the
single microbubble in sonography. However, up to 90 % of
the newly formed bubbles may recondense into the liquid,
resulting in the efficiency of stable bubble generation drop-
ping to even below 1 %. Following vaporization and bubble
formation, the newly created bubbles retain their initial
coating material and undergo rapid expansion (up to
10 μm in diameter) followed by stable oscillations for a
number of cycles eventually coming to rest or rapid shrink-
age or collapse to a radius of less than 1 μm. During the
initial growth and collapse, the bubbles may undergo frag-
mentation and coalescence. There is no dependence of
bubble coalescence rate on ultrasound excitation pressure.
The probability of bubble survival is significantly higher
for coalesced bubbles than the noncoalesced ones follow-
ing vaporization because of increased total volume and
size of the bubble as well as the reduced Laplace pressure,
but decreased with the excitation acoustic pressure. Pres-
ence of a shell reduces the effective surface tension on the
bubble and subsequently the Laplace pressure. Bubbles
with higher concentration of surfactant coating are more
likely to avoid condensation than those with less surfactant.
Coalescence of bubbles may also increase the surfactant
concentration on the final combined bubble. Uncoated PFP
bubbles above the radius of approximately 1 μm do not re-
condense but dissolve on the order of milliseconds [32].
Bubble expansion may not follow the prediction of the
ideal gas law because of the influx of dissolved gases
from the surrounding medium. The influx of dissolved
oxygen into a gas phase inside the emulsion occurs dur-
ing the rarefactional phase of the acoustic wave, followed
by the rectified diffusion of dissolved gases into the
formed bubble. The solubility of gas increases with pres-
sure according to Henry’s law. Although some gases may
be released during the acoustic compression phase, its
degree is less than the uptake due to higher gas solubil-
ity under pressure and a smaller surface area of the
compressed bubbles. When the acoustic wave is termi-
nated, equilibrium corresponding to the ambient pressure
is restored; gases with super-equilibrium concentrations
diffuse out, thus restoring nanodroplets. The noncondens-
able gas will not condense along with the PFC and may
not completely dissolve into the surrounding liquid, leav-
ing a very small bubble of noncondensable gas that easily
nucleates in the next cycle of PFC boiling, leading to an
even larger bubble, and subsequently more diffusion of
noncondensable gas into the bubble. The vapor pressure
of water is 3.17 kPa at 25 °C, an order lower than that of a
small PFC (i.e., 29.1 kPa for PFC6). Thus, PFC bubbles will
form before homogeneous nucleation of water vapor
Fig. 5 Consecutive images of ADV at 15 °C superheat produced by
ultrasound at frequency of 3.5 MHz and pressure of 4.5 MPa with
the initial droplet radius of 5.4 μm, with courtesy of [76]
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bubbles. However, in practice, a small portion of water
evaporates into the first bubbles to form. The first per-
fluoropentane bubble to form contains 3.5 and 4.4 %
water vapor in equilibrium at 25 and 37 °C, respectively.
Perfluorohexane has a lower vapor pressure, so the corre-
sponding values are slightly higher, 9.8 and 11.6 % at 25
and 37 °C, respectively [33]. The complexity in the vapor
components would lead to complicated bubble dynamics
after vaporization.
Till now, some work on the theoretical model of ADV
has been carried out. The bubble dynamics with a phase
shift can be described by Pitt modification of the
Raleigh-Plesset equation [33]

















where μL is the kinematic viscosity of the water phase,
P∞ ¼ Patm þ ρwghþ A sinωt
Pg ¼ Pvap;PFC Ts;PFC
 þ Pvap;H2O Ts;H2O 
P0 ¼ Pg−ΔP
ð5Þ
The vapor pressure of PFCs and water can be obtained
from empirical equations in the form of
Pvap Tsð Þ ¼ exp Aþ B=Ts þ C lnTs þ DTEs
  ð6Þ
where A, B, C, D, and E are constants. This partial differ-
ential equation (PDE) is solved by the explicit Runga-
Kutta routine that uses a fourth order approximation to
calculate and a fifth order to truncate the solution. The
maximum bubble size and collapse velocity are found to
increase with ultrasound amplitude, droplet size, vapor
pressure, and temperature for sufficient time. Sufficient
time means the duration in which the local pressure is
lower than the vapor pressure needed to produce het-
erogeneous or homogeneous nucleation. The liquid sur-
face cools in the liquid evaporation phase while it heats
up during the condensation of gas molecules. Theoret-
ical simulation shows that the radius of the bubble and
the bubble collapse velocity increases almost linearly
with acoustic amplitude. The bubble collapse velocity is
also fairly sensitive to ultrasound frequency, temperature,
the surface tension, as well as initial droplet size.
Bubbles vaporized from droplets are significantly af-
fected by subsequent ultrasound pulses. These secondary
effects, such as microbubble destruction, coalescence fu-
sion, and acoustic radiation force, increase significantly
with acoustic pressure and pulse length interactions.
Therefore, in order to minimally affect the generated
microbubbles, ultrasound pulses with relatively short dur-
ation should be applied to initiate vaporization. Each posi-
tive pressure phase may destroy some bubbles produced
in the prior rarefactional phase, but not completely. Thus,
many previously visualized bubbles re-emerge in the se-
quential rarefactional trough (see Fig. 6). Small bubbles
are more likely to be destroyed by compressive pressure,
while the large ones have resistance to destruction and
high possibility of bubble fusion [34].
The performance of droplets in the acoustic field is de-
termined by many parameters, such as ultrasound
pulses, droplet properties, and environmental variables.
A viscous fluid, limited tissue space, and high elasticity
of surrounding tissue may retard the initial expansion of
the gas bubble generated by ADV and re-condense the
gas nucleus at lower rarefactional pressures. Greater
acoustic amplitude will start bubble growth sooner and
have more total time for growth. Similarly, low-
frequency ultrasound provides a longer time window for
growth. For example, using a 2-cycle sinusoid pulse at
the ultrasound frequency of 1 MHz, bubble formation
was found at rarefactional pressure threshold of 1 MPa,
while at 8 MHz the threshold reached approximately
3 MPa for decafluorobutane nanoemulsions with peak
diameter of 200 nm [34]. The ADV threshold was shown
to be inversely proportional with degree of superheating
and independent of pulse length at clinically relevant
ultrasound frequencies, concentrations of droplet, and
the volume fractions of the PFC, which may be useful
for in vivo application because of limited information of
droplets on site [25, 35, 36]. For longer pulse lengths
(i.e., milliseconds), vaporization can be induced at a de-
creased ultrasound pressure. In comparison, for micro-
sized droplets (90 % < 6 μm), the vaporization drops
with the ultrasound frequency, from 4.5 to 0.75 MPa
peak rarefactional pressure between 1.5 and 8 MHz [8].
It takes a longer time for the microdroplets to com-
pletely vaporize than the submicron ones. However, a
larger emulsion grows into a larger bubble, which is due
to a longer time of subpressurization and a larger sub-
pressurization driving force by the smaller Laplace pres-
sure and the initiation of gas evolution earlier in the
acoustic cycle.
Manufacture
Perfluorocarbon (PFC) including perfluorohexane
(C6F14), dodecafluoropentane (DDFP, C5F12), and deca-
fluorobutane (DFB, C4F10) is a common material for li-
quid emulsion formulation. The use of others, such as
phosphatidylethanolamine (PE), soybean phosphatidylcho-
line (PC), pefluoropentane (PFP), perfluorohexane (PFH),
perfluorobutane (PFB), perfluoro-15-crown-5-ether (PFCE),
perfluorooctylbromide (PFOB, C8F17Br), and perfluorotri-
propylamine was also mentioned [21, 37–40]. Some manu-
facture approaches are listed below.
The first method is similar to that of microbubble
manufacture. Liquefied PFC gas and degassed, deionized
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water were mixed and emulsified with an ultrasonic li-
quid processor for about 30 s. Sometimes, coarse emul-
sification by a vortex mixer or an amalgamator was
performed before the use of sonicator. The resulting
emulsion was poured slowly into albumin or lipid (i.e.,
phospholipids) or polymer solution or surfactant to coat
the droplet, and the shell was used to stabilize the emul-
sion by lowering the surface tension as well as inhibiting
coalescence. These uncoated emulsions are stable for
30–60 min and then start to coalesce after 2–3 h, which
may be due to the nature of hydrocarbon. The surfactant
(i.e., PF68) can interact with phospholipid shells and in-
crease the surface area of each droplet [41]. Subse-
quently, the size of the emulsions decreases with higher
surfactant ratio. But, drug release from the inner core
may be much slower than that from the interfacial shell
[42]. Double emulsion (i.e., oil-in-PFC-in-water) could also
be manufactured using similar method [24]. In addition,
micelles and liposomes could also be produced depending
on the lipid concentration. This method is simple in manu-
facture. In order to have uniform size distribution, the
emulsion needs to pass through filter paper with certain
pore size, which may reduce the manufacturing efficiency.
Droplet could be formulated via extrusion. PFC was
first condensed in a secure container over dry ice, poured
into a glass vial, crimped, and stored at −20 °C to pre-
serve the liquid state. The lipid solution was cooled to
approximately −2 to −5 °C in order to avoid freezing of
the aqueous solution and then mixed with liquid PFC.
The mixture was extruded by several passes through por-
ous membrane filter. After that, the emulsion was stored
in a crimped vial at 4 °C with room air in the headspace
[43]. Both the submicrometer and the micrometer size
(as large as 12–15 μm) droplets were made via extrusion.
Fig. 6 Shadowgraphs of bubbles dynamics using a 20-cycle 1 MHz pulse of 1.45 MPa rarefactional pressure show the droplet vaporization and
fully expansion within 1–2 μs (a–d), microbubble fusion (b–d) (white arrows), and radiation force (d–i), scale bars are 5 μm, with courtesy of [34]
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Microbubble condensation method induced by
pressurization and low temperature allows simple pro-
duction of high-yield nanoemulsions from volatile com-
pounds [43]. Polydisperse distribution of microbubbles
was first produced using standard mechanical agitator,
cooled to room temperature before being immersed in a
CO2/isopropanol bath at −5 to −10 °C, and swirled gen-
tly for about 1 min. Headspace pressure in the vial was
then increased by an adjustable air-pressure source to
revert the emulsions to the liquid state. Pressurization
and temperature condensation of microbubbles are ef-
fective and advantageous in producing ADV nanoemul-
sions in comparison to extrusion and emulsion-based
methods. The condensed droplet size has a peak of
200–300 nm, which corresponding well with the pre-
diction using the ideal gas law from the original bub-
bles in the 1–2 μm range. Variability in the droplet size
(some samples having content below 100 nm while
others having only content greater than 200 nm) may
be due to both insistencies in applied pressure and
temperature at the time of condensation and formation
of micelles and liposomes as a function of lipid concen-
tration. Some content as large as 2–4 μm was also found
in the sample despite of low percentage (1.5–4 %), and the
upper size limit seems to increase with lipid concentra-
tion. The samples with a high number of viable outputs
could be obtained using a similar technique as traditional
microbubble preparation [43].
A microfluidic channel with a flow-focusing structure
can also be used for uniform nanoemulsion production
by forcing a central stream of a dispersed phase and two
side sheath flows of a continuous phase through a small
orifice. The size of droplets including the shell thickness
is well controlled and adjusted by the geometry of
microfluidic channel and flow rate. The minimum size is
the width of the orifice. A high capillary number will lead
to droplet generation in the jetting mode, and breaking off
the tip of the dispersed phase finger due to Rayleigh capil-
lary instability will result in polydisperse production with
a polydispersity index less than 5 % [44]. In addition, over
2 weeks, the mean droplet diameter decreased less than
4 % from 4.5 ± 0.2 μm to 4.3 ± 0.3 μm. However, manufac-
ture speed of this method is not very high. Multiplexing
numerous flow-focusing circuits would scale the through-
put. A 10× scale-up would significantly reduce the pro-
duction time of 1 × 109 droplets on the order of minutes




It is suggested to “starve” cells to death by restricting
their blood supply from the feeder vessel [45]. One
method of treating tumors or other malformations is to
occlude the blood flow to them with gas bubbles, which
can effectively shrink its size. By using focused ultra-
sound, vaporization can be induced intentionally and ac-
curately in the feeder arteries of tumors, resulting in the
occlusion with a high degree of spatial specificity [15, 16].
For frequencies between 1.5 and 8 MHz, the threshold of
peak rarefactional pressure for vaporization decreases
from 4.5 to 0.75 MPa for microdroplets (90 % < 6-μm
diameter) [8]. Large gas bubbles (>30 μm) could be
formed temporarily. Vessel occlusion via ADV has been
explored in rodents and dogs (76-μm mean length and
36-μm mean diameter in capillary and 25-μm mean length
and 11-μm mean diameter in feeder vessel) and may be
translated to clinical use soon [16]. Image-based hyper-
echogenicity from ADV of intra-articular (IA) and intra-
venous (IV) injections after sonic exposure (9.2-MPa peak
negative pressure, 3.5-MHz frequency, 13 cycles, pulse
repetition frequency of 1 kHz and ISPTA of 10 W/cm
2) was
monitored for approximately 90 min, and cortex perfusion
was reduced by >60 % of its original value for more than
1 h, which could be long enough for the onset of cell
death and possible tumor treatment via ischemic necrosis.
However, in these studies, the control kidney on the
contralateral side also showed 18 % of the decrease in re-
gional blood flow relative to the preocclusion baseline,
which may be due to the balance of the urinary output be-
tween the treated and untreated kidneys [15]. IV adminis-
tration results in a lower gas bubble yield, which may be
due to the filtering in the lung, dilution in the blood vol-
ume, or other circulatory effects. So, large volume of the
droplet is required for IV administration in comparison to
IA injection (0.3 vs. 0.03 mL) [46]. However, a raft of re-
cent data shows that starving of a tumor can lead to
increased epithelial-to-mesenchymal transition and meta-
static escape leading to worse overall survival in patients
[47, 48]. Thus, the future of this approach is unclear.
In comparison to the other vascular occlusion
modalities, ADV could improve both diagnostic and
therapeutic ultrasound fields. ADV-based angiography
can provide sensitive feedback on the effect of ultrasonic
therapy in models of pancreatic cancer, breast cancer,
and kidney function. Despite clinical competition from
other modes of vascular occlusion, ADV-induced embo-
lotherapy has great potential in vital organ tissues (brain,
liver, eye, etc.), in which revascularization after thera-
peutic healing is desired. Occlusion can also be accom-
panied by deposition of a chemotherapy drug to increase
local cytotoxic effects and minimize systemic effects [15].
For example, thrombin release from PFC emulsion could
extend the duration of ADV-generated microbubble oc-
clusions. Angiostatin and endostatin suppress the devel-
opment of supply arteries for tumor growth [8].
ADV-generated occlusion also has the potential to insti-
gate hemostasis for vascular damage or internal bleeding.
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Vaporizing in the capillaries could cause the rupture of
these vessels and subsequent red blood cell extravasation.
The encapsulated chemical embolic agent, such as throm-
bin, within a PFC emulsion could be released locally and
noninvasively upon ADV with precision on the order of
millimeters and with no need for ionizing fluoroscopy as
in transcatheter embolization for sustained embolization.
Furthermore, prolonged ischemia generated by vascular
occlusion may activate water soluble, bioreductive pro-
drugs, such as NLCQ-1 [49], encapsulated within the
emulsion [50].
Occlusion is also beneficial in the thermal ablation in-
duced by radio frequency, microwave, or high-intensity
focused ultrasound (HIFU). The blood flow in the tumor
acts as a heat sink, dissipates the heat via vascular cool-
ing, and subsequently reduces the efficacy of the treat-
ment. Reduced blood flow by occlusion could also
induce hypoxia in tumors, but such occlusion prevents
drugs diffusion into the target.
Overall, embolotherapy must be carried out carefully
because many arterial emboli could create infarcts in the
heart or brain or travel to distant vascular bed where
they could cause unwanted arterial occlusion, ischemia,
and potentially infarction [51]. The performance of
ADV-based occlusion is determined by the dynamics of
emulsion and bubbles in the transport (i.e., interaction
with vessel bifurcations downstream) and lodging of the
generated microbubbles in the microvasculature near
the site of vaporization (i.e., sliding along the vascular
space). If the droplets have stealth character, the gener-
ated gas bubbles will easily coalesce into sufficiently
large one(s) to occlude arterioles and capillaries. How-
ever, vascular occlusion may not work well for superfi-
cial tumors. It was found that reduction in blood flow
lowers the core temperature of superficial tumors, which
in turn increases the survival of tumor cells by approxi-
mately two orders of magnitude [52, 53]. Moreover, sig-
nificant growth delays were found to require occlusion
times on the order of 4 h, which requires repetitive
treatments of ADV.
HIFU ablation
Because of the much lower acoustic impedance of gaseous
bubbles in comparison to the surrounding soft tissue, trans-
formation of ultrasonic pressure waves to thermal energy is
much more efficient in the presence of microbubbles, pro-
ducing localized viscous heating. ADV may significantly
and locally enhance thermal delivery in the focal region
from phase-shift nanoemulsions once vaporized for cancer
therapy that hopefully will soon be demonstrated in a pre-
clinical setting. A high degree of spatial and temporal con-
trol of emulsion vaporization could also be beneficial in
generating predictable lesions. Once the ADV pulse was
transmitted and the DDFP droplets were vaporized after
only a 5-cycle exposure at high pressure, a sudden and dra-
matic rise in temperature was recorded at continuous
HIFU exposure at much lower pressure, which is character-
istic of bubble enhanced heating (see Fig. 7). It was found
that the exposure time needed to create similar lesions in
tissue-mimicking phantoms filled with droplets was de-
creased by a factor of 2.5 and the average lesion volume in-
creased by sevenfold using the equal exposure times. In
vivo results in the canine liver were even more promising,
showing a 15-fold increase in lesion volume at equal expos-
ure time to controls without droplets [10].
In the acoustic field, bubble shielding effects are of im-
portance, in which the resident bubbles will reflect or back
scatter the energy of incoming acoustic pulses toward the
source. As a result, it is possible to vaporize additional
nanoemulsions easily in the prefocal region during HIFU
tumor ablation, which could lead to unpredictable prefocal
lesion formation [19]. In HIFU ablation, PFCs with a higher
boiling point, such as PFH, may be more appropriate. Iner-
tial cavitation may significantly reduce the ADV threshold
for HIFU exposures longer than a millisecond. Vaporizing
albumin-coated DDFP microdroplets by heat alone re-
quired temperatures as much as 40 °C above the boiling
point [35], and such discrepancy may increase as the drop-
let size decreases. In addition, vaporized microbubbles may
be manipulated to enhance targeting through acoustic radi-
ation force [54–56].
Drug delivery
Targeted tumor chemotherapy is an active research area
with great potential. The concept of a “magic bullet,” a
drug carrier that responds to a certain stimulus, was first
proposed by Ehrlich in the early twentieth century.
However, most drug delivery techniques do not have the
Fig. 7 Temperature elevations measured during a 10-s continuous
HIFU exposure (2 MHz), and the ADV pulse (2 MHz, 5 cycle, 7.05 MPa
peak negative pressure) was fired at 5 s, which results in a short
temperature drop, and then back to continuous mode for heat
deposition, with courtesy of [19]
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capability of temporally and spatially specific targeting as
ultrasound. The control of localized delivery is especially
important for drugs which possess narrow therapeutic
windows and will allow the deleterious effects on healthy
tissues to be minimized. Ultrasound also provides the
ability of target diagnosis and focusing onto deeply lo-
cated tissues. Drug-loaded microbubbles under ultra-
sound exposure can potentially target drugs to specific
sites. Therapeutic agents are typically incorporated into
the microbubbles by attachment to or insertion in the
shell, complexation of secondary carriers to the micro-
bubble shell, or incorporation within a fluid inside the
shell. Chemotherapeutic drug (i.e., paclitaxel, PTX) was
tightly retained by nanodroplets stabilized with poly(ethyl-
ene oxide)-co-polycaprolactone (PEG-PCL) block copoly-
mer. But, it was effectively released into tumor after
acoustic radiation, which resulted in effective tumor re-
gression [38, 57]. The interaction of ultrasonic pulse with
a payload containing microbubbles involves a number of
mechanisms, such as acoustic cavitation, heating, radi-
ation forces, and sonoporation [58]. Stable bubble cavita-
tion generates strong shear stress close to the bubble
surface, sufficient to shear cell membranes. Inertial cavita-
tion produces shock waves and high-speed microjets,
which also disrupt cell membranes. The transient increase
in cell membrane permeability allows the uptake of drugs,
genes, and peptides from a variety of carriers (polymeric
micelles, liposomes, and nanoemulsions).
Ultrasound can also be used to spatially and tempor-
ally control the release of a therapeutic payload (i.e.,
water-soluble compounds) encapsulated within a PFC
nanoemulsion via ADV. Since PFCs are very hydropho-
bic and lipophobic [59], therapeutic agents are usually
not dissolved directly in the PFC phase but rather in a
secondary phase that is contained within the PFC emul-
sion [60]. The PFC droplet, either in the liquid or gas
state, works as a contrast agent to visualize and confirm
the location of the desired delivery. Higher-intensity
ultrasound is delivered to generate strong cavitational
events to disrupt carriers or cell membranes only if the
location is correct. Because of the absence of endogen-
ous background signal in vivo and the high nuclear mag-
netic resonance (NMR) sensitivity of the 19F atom, PFC
nanoemulsions are ideal agents for cellular and magnetic
resonance molecular imaging. Due to the hydrophobicity
and lipophobicity of the dispersed PFC phase [59], thera-
peutic agents are usually incorporated into the emulsion.
The PFC core is surrounded by a lipid monolayer which
contains a variety of agents including targeting ligands,
imaging agents, and drugs either individually or in com-
bination. One example is shown in Fig. 8 [50]. Plenty of
targeting ligands (~20–40 monoclonal antibodies or
200–400 small-molecule ligands) serve to enhance avid-
ity through multivalent interactions while the PFC core
has high local concentrations of 19F [61, 62]. Fluorine
atoms have the unique property of being both lipopho-
bic and hydrophobic. The PFC nanodroplets were stabi-
lized by some of the block copolymer and the micelles,
with the drug distributed in both the micelles and the
nanodroplet surface.
ADV for drug delivery is still in preclinical stages with
initial applications to treat tumors in mice and retard
tumor growth. Nanodroplets may be able to extravasate
and become acoustically activated or form gas bubbles,
and cavitation may have occurred in the capillaries in
the tumor to increase capillary permeability for drug de-
livery. Systemic doses of anti-angiogenic compounds
(TNP-470) have been lowered by 1000-fold and 60-fold in
the animal and clinical studies using the targeting tech-
niques, respectively [63]. Ultrasound therapy (2 MPa) using
paclitaxel-loaded PFCE nanoemulsions in the breast and
pancreatic cancer animal showed excellent tumor regres-
sion and metastasis suppression as shown in Figs. 9 and 10
[64]. In addition to the mechanical permeabilization of cell
membranes (sonoporation), acoustic radiation force and
microstreaming may push nanoparticles through blood ca-
pillary walls to enhance the drug extravasation, and a
temperature increase may also lead to cell membrane
fluidization [65].
Cavitation activities of UCAs under the exposure of
HIFU pulses have already been illustrated to noninvasively
and effectively cause the reversible blood-brain barrier
(BBB) opening after a 5-s sonication (pulse length of
6.7 ms, pulse repetition frequency of 5 Hz, acoustic pres-
sure of 0.6 MPa as shown in Fig. 11) [66, 67]. Shear stress-
induced endocytosis during stable cavitation is one of the
important mechanisms of increasing the transcellular per-
meability [68]. The cavitation dose can be calculated from
the measured acoustic emission signals and then corre-
lated with the outcome of the BBB opening to estimate
the amount of drug delivered to the targeted region. Simi-
lar to drug delivery in the tumor, once entered into the
interstitial cerebral space, the droplets could then be va-
porized acoustically activated to form microbubbles out-
side the constraints of the cerebral microvessels as a new
class of contrast agents. Such extravascularly activated
microbubbles can enhance drug delivery at deeply located
sites in the brain tissue or in regions with relatively low
vasculature density [27]. Stable cavitation dose increases
in a linear relationship with the acoustic pressure for both
nanodroplet (R2 = 0.99) and microbubbles (R2 = 0.93).
There was no detectable inertial cavitation dose at
the pressure up to 0.6 MPa, suggesting no bubble
fragmentation. However, the inertial cavitation dose
slightly increased after microbubble injection at
0.60 MPa (P = 0.017). Overall, nanodroplets had a higher
pressure threshold for BBB opening but a lower stable cavi-
tation threshold than the microbubbles. Although similar
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homogenous dextran distribution throughout the targeted
volume was achieved using both vaporized nanodroplet
and microbubbles under the same acoustic exposure
settings, microbubble-mediated BBB opening resulted
in minor hippocampus damage at 0.60 MPa. Therefore,
a higher acoustic pressure could be applied to nanodro-
plets safely because of its higher threshold for inducing
inertial cavitation than that of microbubbles. These two
agents have the same composition, lipid-encapsulated
perfluorobutane cores, but the nanodroplet has both
Fig. 8 Schematic diagram of a liquid perfluorocarbon nanoemulsion with targeting ligands and payload
Fig. 9 Intravital fluorescence images of subcutaneous pancreatic
tumors in mice injected with empty droplets (a and b) or PTX-loaded
1 % PFCE/5 % PEG-PDLA droplets (c and d) 6 h before and three days
after ultrasound therapy (50 s exposure in a circle of 4-mm diameter,
1 MHz frequency, acoustic intensity of 54 W/cm2), and photographs of
the tumors taken 12 days after the treatment (e and f), with courtesy
of [64]
Fig. 10 A 2 % PFCE nanoemulsion stabilized with PEG-PCL copolymer
was systemically injected to a pancreatic tumor bearing mouse every
2 h 200 μl each for four times and a total PFCE dose of 2 mmol/kg.
Coronal slices in the 19F MR images superimposed on the low
resolution proton anatomic images (a and b) were recorded an
hour after the last nanodroplet injection (7 h after the start).
Multiple liver metastases (long thin arrows) and transparent large
tumor (thick arrow) are revealed at the necropsy of the mouse
(c), with courtesy of [64]
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the liquid and gaseous states of the cores. The large
microbubbles formed by nanodroplets vaporization
may enhance the shear stress induced during stable
cavitation to endothelial cells along the microvessels
more efficiently than UCA microbubbles, thus increas-
ing the number of BBB disrupted sites to facilitate a
more homogenous dextran delivery distribution with-
out concerns regarding undesired tissue injury due to
inertial cavitation.
Histotripsy
Using extremely short but high-pressure pulses, histo-
tripsy generates a dense cloud of cavitation microbub-
bles that fractionates tissue. Synthetic nanodroplets that
encapsulate a PFP core will transition upon exposure to
ultrasound pulses into gas microbubbles, which will rap-
idly expand and collapse resulting in disruption of cells
similar to the histotripsy process but at a significantly
lower acoustic pressure. The significantly reduced cavita-
tion threshold will allow histotripsy to be selectively de-
livered to the tumor tissue and greatly enhance the
treatment efficiency while sparing neighboring healthy
tissue. A bubble cloud occurs after the first pulse, and
then the number of bubbles inside the cloud signifi-
cantly decreased with increasing number of pulses and
finally will be destroyed by the cavitation process, which
is more pronounced at higher frequencies. Nanodroplet-
mediated histotripsy (NMH) created consistently well-
defined fractionation of the cells in agarose tissue phan-
tom similar to the lesions generated by histotripsy alone
but at a significantly lower pressure (see Fig. 12). Once
the cavitation bubble cloud is initiated, the histotripsy
process can be maintained at a much less pressure than
that needed for initiation. The resulting gas bubbles can
function as ultrasound contrast agents, which will allow
the histotripsy to be seen on sonography for real-time
guidance and monitoring. The energetic bubble activity
disrupts adjacent cells and eventually produces complete
fractionation of cells in the target tissue into a liquefied
homogenate. A peak negative pressure below 10 MPa,
no microbubbles were observed and no lesions were vi-
sualized. In comparison, in control gels without nano-
droplets, no lesions were formed at any treatments in
this pressure range. Lower frequency would improve the
effectiveness of NMH by increasing the size of the focal
region, increasing bubble expansion, the number of bub-
bles generated, and the lifespan of bubble cloud which is
due to the enhanced bubble expansion results in a larger
population of residual nuclei and a corresponding in-
crease in dissolution time. No bubbles were observed
after 100 pulses delivered to the samples. NMH will be
applied at a higher pulse repetition frequency to sustain
cavitation for the duration of the treatment. Nanodroplet
containing a higher boiling point perfluorocarbon, such
as perfluorohexane, would re-condense into a liquid and
remain sustainable nuclei over multiple pulses, which
may be a major benefit for NMH therapy. However,
higher boiling point droplets may also require a higher
pressure to generate cavitation [69].
Discussion
In the past decades, extensive studies have been carried
out to understand the mechanism of ADV, simulate the
bubble dynamics in the acoustic field, and apply this
phenomenon in medical investigation. Due to the com-
plexity involved in this event, including nucleation,
vaporization, oscillation, recondensation, and dissol-
ution, and a large range of droplet size used in the study
(both submicron and micron), more effort is required to
fully understand the mechanisms. Some insights have
already been obtained owing to the use of ultrafast pho-
tography with a large number of frames. Meanwhile, in
Fig. 11 Representative fluorescence images in the targeted and the control (insets) hippocampi when nanodroplets (top) or microbubbles (bottom) and
fluorescently labeled 3 kDa dextran were used to mediate BBB opening at frequency of 1.5 MHz, pulse duration of 6.7 ms, pulse repletion frequency of
5 Hz, exposure duration of 5 min, various peak-rarefactional pressures of 0.15 MPa (a and f), 0.225 MPa (b and g), 0.30 MPa (c and h), 0.45 MPa (d and i),
and 0.60 MPa (e and j), the scale bar is 1 mm, with courtesy of [27]
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order to enhance its clinical performance and safety for
quick transition and wide acceptance of the applications,
some aspects, but not limited, may have more interests for
continuous investigation in the following days.
Inclusion of paramagnetic nanoparticles, fluorescent
nanoparticles, and radioisotopes enables the detection
of PFC emulsions in 1H MR T1-weighted imaging,
SPECT-CT, and optical fluorescence imaging [70–73].
Fluorine NMR has a large chemical shift range
(~300 ppm) allowing the examination of multiple
agents simultaneously with minimal signal overlap.
The integral of quantitative NMR signal, such as the
fluorine atoms within the core of PFC nanodroplets,
is proportional to the amount of particles being inter-
rogated for MR molecular imaging. The 19F isotope
of fluorine has a natural abundance of near 100 %,
but virtually zero in the biological presence. There-
fore, the chemical shift of the PFCs can be easily dif-
ferentiated from the background. The nanoparticles
for molecular imaging must have a long circulation
time, highly sensitive and selective binding to the epi-
tope of interest, prominent contrast-to-noise enhance-
ment, acceptable toxicity, ease of clinical use, and
compatibility with commercially available imaging sys-
tems. Multifunctional activity can be realized by in-
corporating more targeting ligands, imaging agents,
and drugs into the formulation simultaneously. Mate-
rials can be covalently or noncovalently linked to the
particle surface, dissolved in the coating, or carried in
particle interiors for cellular deposition and activation.
Multivalent interactions between high-avidity agents
and cell surface may partially overcome the dissoci-
ation of the targeting ligand itself in the nanomolar
range [10].
Most of the ADV techniques mentioned above are still
in preclinical studies but have potential for clinical use in
specialty applications. Overall, ADV has a bright future
because the small size of nanodroplets greatly reduces the
rate of clearance compared to larger ultrasound contrast
agent bubbles and yet provides the advantages of ultra-
sonographic contrast, acoustic cavitation, and acceptable
toxicity of conventional perfluorocarbon contrast agent
bubbles. Injection of fluorocarbon emulsions induces
short- and long-term effects that spontaneously resolve
within 12–24 h. The adverse effect of “pulmonary hyper-
inflation” observed upon administration to humans is less
likely than that for rabbits, pigs, or monkeys. In addition,
toxicity of surfactants that stabilize the droplets must also
be considered. Natural phospholipids, polysaccharides,
and human proteins may be the best stabilizing agents to
use.
The capability of simultaneous imaging and targeted
drug delivery of nanoparticles shows great promise
for individualizing therapeutics and could enable con-
clusive assurance that the drug is reaching the
intended target in a much higher effective drug con-
centration. Imaging can also be used to monitor dis-
tribution of released drugs. For example, liposome
colabeled with gadolinium (Gd) could allow MRI
monitoring. Fluorescent markers on the drug can be
detected using bioluminescent imaging system. Such
information allows optimal timing of external stimu-
lus application. Furthermore, approval by regulatory
agencies may be very slow although the FDA has spe-
cific pathways for combined devices that go through
two separate departments [74]. This regulatory obs-
tacle may temper the enthusiasm of pharmaceutical
companies to pursue development, given the expense
and risk of clinical trials [10]. ADV is a complex
process and not a fully understood phenomenon, in-
volving many variables that are not always straightfor-
ward to regulate for safety and may be some variables
not taken into consideration yet.
New treatment strategies will be developed, and op-
eration parameters will be optimized in the following
years to enhance the outcome. The internalization of
targeted or nontargeted droplets into cells and subse-
quent vaporization could lead to new tissue-specific
Fig. 12 Optical images of nanodroplet-mediated cell fractionation. Images of cavitation bubble cloud (dark) and lesions (white) generated in the RBC
agarose gel (gray) using nanodroplet-mediated histotripsy at different pressure levels. A total of 2000 2-cycle pulses at a driving frequency of 500 kHz
and a pulse repetition frequency of 10 Hz were used for each treatment with peak negative pressure from 6.2 to 20.7 MPa, with courtesy of [77]
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therapy. A co-injection of both nano- and microdro-
plets could simultaneously release drugs in the tumor
interstitium by extravasated nanodroplets and occlude
the vascular space by larger ones [10]. If the lowest
vaporization pressure is required, the PFC with the
lowest boiling point allows for stable circulation at
physiological temperatures will be used. The optimal
particle size of the emulsion should result in a vascu-
lar persistence that is clinically efficacious while limit-
ing deep-tissue retention. Droplets may remain stable
until a desired “activation pulse” is delivered to create
desired bioeffects. More measurements are required
to establish the acoustic thresholds for gas expansion
as a function of acoustic parameters (frequency, amp-
litude, pulse length, etc.) and the characteristics of
the droplets (chemical composition, size, stabilizing
surfactants, temperature, etc.) [75].
Conclusions
Acoustic droplet vaporization, a phenomenon of phase
shift from liquid to gas in the acoustic field, is a new ap-
proach of producing bubbles to enhance the bioeffects
of ultrasound therapy with high accuracy of spatial and
temporal control. The burst produced from commercially
available echosonographic systems is strong enough to in-
duce ADV for microdroplets. Submicron size of droplets
allows penetration into tumors via EPR effects and much
prolonged half-life time in the circulating system, over-
coming the limitation of the commonly used ultrasound
contrast agents (i.e., microbubbles), but needs more
acoustic pressure to vaporize. Its recent applications, such
as vessel occlusion, thermal ablation, drug delivery, and
histotripsy, have already shown very promising results. Al-
though most in vivo studies are still in the preclinical
stage, translation into clinics may occur in the following
years. In comparison to bubble cavitation of microbubbles,
that of vaporized droplets has more stable cavitation and
less inertial cavitation, which makes ADV good candidate
for localized drug delivery with the minimal damage to
the surrounding tissue. In order to understand the mech-
anism more clearly, effort in the theoretical modeling and
experimental observation is highly desired.
Competing interests
The author declares that he has no competing interests.
Received: 22 June 2015 Accepted: 2 November 2015
References
1. Stride E, Coussios C. Cavitation and contrast: the use of bubbles in
ultrasound imaging and therapy. Proc Inst Mech Eng Part H: J Eng Med.
2010;224:171–91.
2. Miller MW, Miller DL, Brayman AA. A review of in vitro bioeffects of inertial
ultrasonic cavitation from a mechanistic perspective. Ultrasound Med Biol.
1996;22:1131–54.
3. Petit B, Bohren Y, Gaud E, Bussat P, Arditi M, Yan F, et al. Sonothrombolysis:
the contribution of stable and inertial cavitation to clot lysis. Ultrasound
Med Biol. 2015;41:1402–10.
4. Kooiman K, Vos HJ, Versluis M, de Jong N. Acoustic behavior of
microbubbles and implications for drug delivery. Adv Drug Deliv Rev.
2014;72:28–48.
5. Chung DJ, Cho SH, Lee JM, Hahn S-T. Effect of microbubble contrast agent
during high intensity focused ultrasound ablation on rabbit liver in vivo. Eur
J Radiol. 2012;81:e519–23.
6. Carlisle R, Choi J, Bazan-Peregrino M, Laga R, Subr V, Kostka L, Ulbrich K,
Coussios C-C, Seymour LW. Enhanced tumor uptake and penetration of
virotherapy using polymer stealthing and focused ultrasound. J Natl Cancer
Inst. 2013; djt305.
7. Graham SM, Carlisle R, Choi JJ, Stevenson M, Shah AR, Myers RS, et al.
Inertial cavitation to non-invasively trigger and monitor intratumoral
release of drug from intravenously delivered liposomes. J Control
Release. 2014;178:101–7.
8. Kripfgans OD, Fowlkes JB, Miller DL, Eldevik OP, Carson PL. Acoustic
droplet vaporization for therapeutic and diagnostic applications.
Ultrasound Med Biol. 2000;26:1177–89.
9. Zhang M, Fabiilli ML, Haworth KJ, Padilla F, Swanson SD, Kripfgans OD, et al.
Acoustic droplet vaporization for enhancement of thermal ablation by high
intensity focused ultrasound. Acad Radiol. 2011;18:1123–32.
10. Sheeran PS, Dayton PA. Phase-change contrast agents for imaging and
therapy. Curr Pharm Des. 2012;18:2152–65.
11. Lattin JR, Pitt WG, Belnap DM, Husseini GA. Ultrasound-induced calcein release
from eLiposomes. Ultrasound Med Biol. 2012;38:2163–73.
12. Crouse LJ, Cheirif J, Hanly DE, Kisslo JA, Labovitz AJ, Raichlen JS, et al.
Opacification and border delineation improvement in patients with
suboptimal endocardial border definition in routine echocardiography: results
of the phase III Albunex multicenter trial. J Am Coll Cardiol. 1993;22:1494–500.
13. Lindner JR, Dent JM, Moos SP, Jayaweera AR, Kaul S. Enhancement of left
ventricular cavity opacification by harmonic imaging after venous injection of
Albunex. Am J Cardiol. 1997;79:1657–62.
14. Ives AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and
retention effect for tumor targeting. Drug Deiscov Today. 2006;11:812–8.
15. Kripfgans OD, Orifici CM, Carson PL, Ives K, Eldevik OP, Fowlkes JB. Acoustic
droplet vaporization for temporal and spatial control of tissue occlusion: a
kidney study. IEEE Trans Ultrason FerroelectrFreq Control. 2005;52:1101–10.
16. Zhang M, Fabiilli ML, Haworth KJ, Fowlkes JB, Kripfgans OD, Roberts WW, et al.
Initial investigation of acoustic droplet vaporization for occlusion in canine
kidney. Ultrasound Med Biol. 2010;36:1691–703.
17. Shiraishi K, Endoh R, Furuhata H, Nishihara M, Suzuki R, Kazuo M, et al. A
facile preparation method of a PFC-containing nano-sized emulsion for
theranostics solid tumors. Int J Pharm. 2011;421:379–87.
18. Sheeran PS, Wong VP, Luois S, McFarland RJ, Ross WD, Feingold S, et al.
Decafluorobutane as a phase-change contrast agent for low-energy
extravascular ultrasonic imaging. Ultrasound Med Biol. 2011;37:1518–30.
19. Zhang P, Porter T. An in vitro study of a phase-shift nanoemulsion: a
potential nucleation agent for bubble-enhanced HIFU tumor ablation.
Ultrasound Med Biol. 2010;36:1856–66.
20. Rapoport N. Phase-shift, stimuli-responsive perfluorocarbon nanodroplets for
drug delivery to cancer. Wiley Interdisc Rev: Nanomedicine
Nanobiotechnology. 2012;4:492–510.
21. Rapoport N, Kennedy AM, Shea JE, Scaife CL, Nam KH. Controlled and
targeted tumor chemotherapy by ultrasound-activated nanoemulsions/
microbubbles. J Control Release. 2009;138:268–76.
22. Wong A, Kripfgans OD, Qamar A, Fowlkes JB, Bull JL. Bubble evolution in
acoustic droplet vaporization at physiological temperature via ultra-high
speed imaging. Soft Matter. 2011;7:4009–16.
23. Qamar A, Wong ZZ, Fowlkes JB, Bull JL. Dynamics of acoustic droplet
vaporization in gas embolotherapy. Appl Phys Lett. 2010;96:143702.
24. Shpak O, Kokhuis TJ, Luan Y, Lohse D, de Jong N, Fowlkes JB, et al.
Ultrafast dynamics of the acoustic vaporization of phase-change
microdroplets. J Acoust Soc Am. 2013;134:1610–21.
25. Fabiilli ML, Haworth KJ, Fakhri NH, Kripfgans OD, Carson PL, Fowlkes JB.
The role of inertial cavitation in acoustic droplet vaporization. IEEE Trans
Ultrason Ferroelectr Freq Control. 2009;56:1006–17.
26. Singh R, Husseini GA, Pitt WG. Phase transitions of nanoemulsions using
ultrasound: experimental observations. Ultrason Sonochem.
2012;19:1120–5.
Zhou Journal of Therapeutic Ultrasound  (2015) 3:20 Page 16 of 18
27. Chen CC, Sheeran PS, Wu S-Y, Olumolade OO, Dayton PA, Konofagou EE.
Targeted drug delivery with focused ultrasound-induced blood-brain barrier
opening using acoustically-activated nanodroplets. J Control Release.
2013;172:795–804.
28. Kripfgans OD, Fabiilli ML, Carson PL, Fowlkes JB. On the acoustic
vaporization of micrometer-sized droplets. J Acoust Soc Am.
2004;116:272–81.
29. Kang S-T, Yeh C-K. Intracellular acoustic droplet vaporization in a single
peritoneal macrophage for drug delivery applications. Langmuir.
2011;27:13183–8.
30. Shpak O, Verweij M, Vos HJ, de Jong N, Lohse D, Versluis M. Acoustic
droplet vaporization is initiated by superharmonic focusing. PNAS.
2014;111:1697–702.
31. Li DS, Kripfgans OD, Fabiilli ML, Fowlkes JB, Bull JL. Initial nucleation site
formation due to acoustic droplet vaporziation. Appl Phys Lett.
2014;104:063703.
32. Reznik N, Shpak O, Gelderblom EC, Williams R, de Jong N, Versluis M,
et al. The efficiency and stability of bubble formation by acoustic
vaporization of submicron perfluorocarbon droplets. Ultrasonics.
2013;53:1368–76.
33. Pitt WG, Singh RN, Perez KX, Husseini GA, Jack DR. Phase transitions of
perfluorocarbon nanoemulsion induced with ultrasound: a mathematical
model. Ultrason Sonochem. 2014;21:879–91.
34. Sheeran PS, Matsunaga TO, Dayton PA. Phase-transition thresholds and
vaporization phenomena for ultrasound phase-change nanoemulsions
assessed via high-speed optical microscopy. Phys Med Biol.
2013;58:4513.
35. Giesecke T, Hynynen K. Ultrasound-mediated cavitation thresholds
of liquid perfluorocarbon droplets in vitro. Ultrasound Med Biol.
2003;29:1359–65.
36. Lo AH, Kripfgans OD, Carson PL, Rothman ED, Fowlkes JB. Acoustic
droplet vaporization threshold: effects of pulse duration and contrast
agent. IEEE Trans Ultrason Ferroelectr Freq Control. 2007;54:933–46.
37. Rapoport N. Physical stimuli-responsive polymeric micelles for anti-cancer
drug delivery. Prog Polym Sci. 2007;32:962–90.
38. Rapoport N, Gao Z, Kennedy AM. Multifunctional nanoparticles for
combining ultrasonic tumor imaging and targeted chemotherapy.
J Natl Cancer Inst. 2007;99:1095–106.
39. Rapoport N, Christensen DA, Kennedy AM, Nam KH. Cavitation properties of
block copolymer stabilized phase-shift nanoemulsions used as drug carriers.
Ultrasound Med Biol. 2010;36:419–29.
40. Rapoport N, Efros AL, Christensen DA, Kennedy AM, Nam KH. Microbubble
generation in phase-shift nanoemulsions used as anticancer drug carriers.
Bub Sci Eng Technol. 2009;1:31–9.
41. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice
of intravenously injected camptothecin solid lipid nanoparticles and
targeting effect on brain. J Control Release. 1999;59:299–307.
42. Fang J-Y, Hung C-F, Hua S-C, Hwang T-L. Acoustically active
perfluorocarbon nanoemulsions as drug delivery carriers for camptothecin:
drug release and cytotoxicity against cancer cells. Ultrasonics.
2009;49:39–46.
43. Sheeran PS, Luois S, Dayton PA, Matsunaga TO. Formulation and acoustic
studies of a new phase-shift agent for diagnostic and therapeutic
ultrasound. Langmuir. 2011;27:10412–20.
44. Bardin D, Martz TD, Sheeran PS, Shih R, Dayton PA, Lee AP. High-speed,
clinical-scale microfluidic generation of stable phase-change droplets for
gas embolotherapy. Lab Chip. 2011;11:3990–8.
45. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of
experimental cancer does not induce acquired drug resistance. Nature.
1997;390:404–7.
46. Kripfgans OD, Fowlkes JB, Woydt M, Eldevik OP, Carson PL. In vivo droplet
vaporization for occlusion therapy and phase aberration correction.
Ultrason Ferroelectr Freq Control IEEE Trans. 2002;49:726–38.
47. Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and
future perspectives. Cancer Lett. 2012;320:130–7.
48. Schlappack O, Zimmermann A, Hill R. Glucose starvation and acidosis: effect
on experimental metastatic potential. DNA content and MTX resistance of
murine tumour cells. Br J Cancer. 1991;64:663.
49. Papadopoulou MV, Ji M, Bloomer WD. NLCQ-1, a novel hypoxic cyototoxin:
potentiation of melphalan, cisDDP and cyclophosphamide in vivo. Int J
Radiat Oncol Biol Phys. 1998;42:775–9.
50. Fabiilli ML, Lee JA, Kripfgans OD, Carson PL, Fowlkes JB. Delivery of water-
soluble drugs using acoustically triggered perfluorocarbon double
emulsions. Pharm Res. 2010;27:2753–65.
51. Lyaker MR, Tulman DB, Dimitrova GT, Pin RH, Papadimos TJ. Arterial
embolism. Int J Crit Illn Inj Sci. 2013;3:77–87.
52. Parkins CS, Hill SA, Lonergan SJ, Horsman MR, Chadwick JA, Chaplin DJ.
Ischaemia induced cell death in tumors: importance of temperature
and pH. Int J Radiat Oncol* Biol* Phys. 1994;29:499–503.
53. Chaplin D, Horsman M. The influence of tumour temperature on ischemia-
induced cell death: potential implications for the evaluation of vascular
mediated therapies. Radiother Oncol. 1994;30:59–65.
54. Dayton PA, Klibanov A, Brandenburger G, Ferrara K. Acoustic radiation force
in vivo: a mechanism to assist targeting of microbubbles. Ultrasound Med
Biol. 1999;25:1195–201.
55. Rychak JJ, Klibanov AL, Hossack JA. Acoustic radiation force enhances
targeted delivery of ultrasound contrast microbubbles: in vitro verification.
IEEE Trans Ultrason Ferroelectr Freq Control. 2005;52:421–33.
56. Lum AFH, Borden MA, Dayton PA, Kruse DE, Simon SI, Ferrara KW.
Ultrasound radiation force enables targeted deposition of model drug
carriers loaded on microbubbles. J Control Release. 2006;111:128–34.
57. Gao Z, Kennedy AM, Christensen DA, Rapoport N. Drug-loaded nano/
microbubbles for combining ultrasonography and targeted chemotherapy.
Ultrasonics. 2008;48:260–70.
58. Zhou Y. Ultrasound-mediated drug/gene delivery in solid tumor treatment.
J Healthcare Eng. 2013;4:223–54.
59. Riess JG. Oxygen carriers (“blood substitutes”)-raison d’etre, chemistry, and
some physiology. Chem Rev. 2001;101:2797–919.
60. Couture O, Faivre M, Pannacci N, Babataheri A, Servois V, Tabeling P, et al.
Ultrasound internal tattooing. Medical Physics. 2011;38:1116–23.
61. Lanza GM, Wickline SA. Targeted ultrasonic contrast agents for molecular
imaging and therapy. Prog Cardiovasc Dis. 2001;44:13–31.
62. Lanza GM, Wickline SA. Targeted ultrasonic contrast agents for molecular
imaging and therapy. Curr Probl Cardiol. 2003;28:625–53.
63. Kaneda MM, Caruthers S, Lanza GM, Wickline SA. Perfluorocarbon
nanoemulsions for quantitative molecular imaging and targeted
therapeutics. Ann Biomed Eng. 2009;37:1922–33.
64. Rapoport N, Nam K-H, Gupta R, Gao Z, Mohan P, Payne A, et al. Ultrasound-
mediated tumor imaging and nanotherapy using drug loaded, block
copolymer stabilized perfluorocarbon nanoemulsions. J Control Release.
2011;153:4–15.
65. Hayat H, Friedbert I. Heat-induced alterations in cell membrane permeability
and cell inactivation of transformed mouse fibroblasts. Int J Hyperthermia.
1986;2:369–78.
66. Mesiwala AH, Farrell L, Wenzel HJ, Silbergeld DL, Crum LA, Winn HR, et al.
High-intensity focused ultrasound selectively disrupts the blood-brain
barrier in vivo. Ultrasound Med Biol. 2002;28:389–400.
67. Vykhodtseva N, McDannold N, Hynynen K. Progress and problems in the
application of focused ultrasound for blood–brain barrier disruption.
Ultrasonics. 2008;48:279–96.
68. McDannold N, Vykhodtseva N, Hynynen K. Targeted disruption of the
blood–brain barrier with focused ultrasound: association with cavitation
activity. Phys Med Biol. 2006;51:793–807.
69. Vlaisavljevich E, Aydin O, Durmaz YY, Lin K-W, Fowlkes JB, ElSayed M, et al.
Effects of ultrasound frequency on nanodroplet-mediated histotripsy.
Ultrasound Med Biol. 2015;41:2135–47.
70. Lanza G, Winter P, Caruthers S, Hughes M, Hu G, Schmieder A, et al.
Theragnostics for tumor and plaque angiogenesis with perfluorocarbon
nanoemulsions. Angiogenesis. 2010;13:189–202.
71. Lanza GM, Winter PM, Neubauer AM, Caruthers SD, Hockett FD, Wickline SA.
1 H/19 F magnetic resonance molecular imaging with perfluorocarbon
nanoparticles. Curr Top Dev Biol. 2005;70:57–76.
72. Caruthers SD, Neubauer AM, Hockett FD, Lamerichs R, Winter PM, Scott MJ,
et al. In vitro demonstration using 19F magnetic resonance to augment
molecular imaging with paramagnetic perfluorocarbon nanoparticles at
1.5 tesla. Investig Radiol. 2006;41:305–12.
73. Partlow KC, Chen J, Brant JA, Neubauer AM, Meyerrose TE, Creer MH, et
al. 19F magnetic resonance imaging for stem/progenitor cell tracking
with multiple unique perfluorocarbon nanobeacons. FASEB J.
2007;21:1647–54.
74. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol
Pharmaecutics. 2011;8:2101–41.
Zhou Journal of Therapeutic Ultrasound  (2015) 3:20 Page 17 of 18
75. Lin C-Y, Pitt WG. Acoustic droplet vaporization in biology and medicine.
BioMed Res Int. 2013;2013.
76. Shpak O, Stricker L, Versluis M, Lohse D. The role of gas in ultrasonically
driven vapor bubble growth. Phys Med Biol. 2013;58:2523.
77. Vlaisavljevich E, Durmaz YY, Maxwell A, ElSayed M, Xu Z. Nanodroplet-
mediated histotripsy for image-guided targeted ultrasound cell ablation.
Theranostics. 2013;3:851–64.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zhou Journal of Therapeutic Ultrasound  (2015) 3:20 Page 18 of 18
